1. Home
  2. NXGL vs NEUP Comparison

NXGL vs NEUP Comparison

Compare NXGL & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

N/A

Current Price

$0.82

Market Cap

9.8M

Sector

Health Care

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.74

Market Cap

23.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NXGL
NEUP
Founded
1997
1996
Country
United States
United States
Employees
19
8
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8M
23.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NXGL
NEUP
Price
$0.82
$4.74
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
149.4K
45.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.28
N/A
Revenue Next Year
$42.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$3.65
52 Week High
$3.25
$21.31

Technical Indicators

Market Signals
Indicator
NXGL
NEUP
Relative Strength Index (RSI) 29.40 66.00
Support Level N/A $3.92
Resistance Level $2.70 $5.06
Average True Range (ATR) 0.12 0.24
MACD -0.02 0.04
Stochastic Oscillator 20.24 76.47

Price Performance

Historical Comparison
NXGL
NEUP

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: